Dermatophagoides farinae allergen-specific Immunoglobulin E (Der f-sIgE)

Dermatophagoides farinae allergen-specific Immunoglobulin E (IgE) refers to the polyclonal antibody population that recognizes proteins from the American house dust mite, primarily the major allergens Der f 1 and Der f 2 (Thomas et al., 2002, Allergy). These IgE molecules play a critical role in the adaptive immune system's hypersensitivity response by binding to high-affinity FcεRI receptors on mast cells and basophils. Upon subsequent exposure to house dust mite allergens, the cross-linking of surface-bound IgE triggers the degranulation of these effector cells, releasing potent inflammatory mediators such as histamine and cysteinyl leukotrienes (Galli et al., 2008, Nature). This cascade is a primary driver of chronic allergic diseases, including allergic asthma, perennial allergic rhinitis, and atopic dermatitis. Therapeutic interventions targeting this system include monoclonal antibodies like omalizumab, which neutralize circulating IgE (FDA Label, Xolair), and allergen-specific immunotherapy (AIT), which aims to modify the underlying immune response by inducing regulatory T cells and protective IgG4 antibodies (Jutel et al., 2015, JACI).

Other names

House dust mite-specific IgEAnti-Der f IgEDer f 1 specific IgEDer f 2 specific IgEHDM-specific IgE

Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils, thereby limiting the release of mediators of the allergic response. Allergen-specific immunotherapy (AIT) induces peripheral T-cell tolerance, increases the production of regulatory cytokines like IL-10, and promotes the synthesis of allergen-specific IgG4 antibodies that act as blocking antibodies to prevent IgE-allergen binding.